蘭德資本 RAND 深 滬
已收盤 08-15 16:00:00 美东时间
15.21
+0.005
+0.03%
華盛通- 最 高16.10
- 今 開15.00
- 成交量 8642股
- 最 低 15.00
- 昨 收 15.205
- 總市值 4517.07万
- 52周最高 31.31
- 市盈率 靜 4.45
- 換手率 0.29%
- 52周最低 13.82
- 委 比 -52.52%
- 總股本 296.98万
- 歷史最高 31.31
- 量 比 1.22
- 振 幅 7.23%
- 歷史最低 -2.54
- 每 手 1
- 風險率 2.73%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Nutri-Grain Rolls Out the Nutri-Grain Lounge to Give Teachers the Break They Deserve
The ultimate mobile teachers' lounge is hitting the road — and one school is about to get the surprise of the year. CHICAGO, Aug. 12, 2025 /PRNewswire/ -- Nutri‑Grain® is setting a new stand...
08-12 20:00
WESTERN MIDSTREAM ANNOUNCES SECOND-QUARTER POST-EARNINGS INTERVIEW WITH CFO, KRISTEN SHULTS AND SVP, COMMERCIAL, JON VANDENBRAND
AND PARTICIPATION IN UPCOMING INVESTOR CONFERENCES HOUSTON, Aug. 11, 2025 /PRNewswire/ -- Today Western Midstream Partners, LP (NYSE: WES) ("WES" or the "Partnership") announced that tomorro...
08-11 19:00
Rand Capital Q2 Adj. EPS $0.33 Down From $0.44 YoY, Sales $1.602M Down From $2.136M YoY
Rand Capital (NASDAQ:RAND) reported quarterly earnings of $0.33 per share. This is a 25 percent decrease over earnings of $0.44 per share from the same period last year. The company reported $1.602 million in sales this
08-04 20:31
Earnings Scheduled For August 4, 2025
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is likely to rep...
08-04 16:32
LEGRAND (0MW7) Gets a Buy from Barclays
Barclays analyst Lars Brorson maintained a Buy rating on LEGRAND today and set ...
08-01 16:28
Rand Capital declares $0.29 dividend
Rand Capital (NASDAQ:RAND) declares $0.29/share quarterly dividend, in line with previous. Forward yield 6.11% Payable Sept. 12; for shareholders of record Aug. 29; ex-div Aug. 29. See RAND Dividend S...
07-29 04:47
Kepler Capital Remains a Buy on LEGRAND (0MW7)
Kepler Capital analyst William Mackie maintained a Buy rating on LEGRAND on Jul...
07-19 09:46
LEGRAND (0MW7) Gets a Sell from UBS
UBS analyst Andre Kukhnin maintained a Sell rating on LEGRAND today and set a p...
07-18 18:28
No Accelerated FDA Approval For Edgewise's Rare Muscular Disease Drug; Shares Fall
Edgewise reports sustained functional stability in Becker patients and selects Phase 3 dose for Duchenne after positive Phase 2 trial data.
06-27 01:29
Edgewise falls after data for muscular dystrophy therapy
Edgewise Therapeutics (NASDAQ:EWTX) lost ~9% in the morning hours on Thursday after the company posted data from clinical trials for its lead asset, sevasemten, against Becker and Duchenne muscular dy...
06-26 22:20
